In this work, three isoxazoline-thiazolidine-2,4-dione derivatives were synthesized and characterized by FT-IR, 1 H-NMR, 13 C-NMR and ESI-MS spectrometry. All compounds have been investigated for their a-amylase and a-glucosidase inhibitory activities. In vitro enzymatic evaluation revealed that all compounds were inhibitory potent against a-glucosidase with IC 50 values varied from 40.67 ± 1.81 to 92.54 ± 0.43 mM, and a-amylase with IC 50 in the range of 07.01 ± 0.02 to 75.10 ± 1.06 mM. One of the tested compounds were found to be more potent inhibitor compared to other compounds and standard drug Acarbose (IC 50 glucosidase ¼ 97.12 ± 0.35 mM and IC 50 amylase ¼ 2.97 ± 0.01 lM). All compounds were then evaluated for their acute toxicity in vivo and shown their safety at a high dose with LD > 2000mg/kg BW. A cell-based toxicity evaluation was performed to determine the safety of compounds on liver cells, using the MTT assay against HepG2 cells, and the results shown that all compounds have non-toxic impact against cell viability and proliferation compared to reference drug (Pioglitazone). Furthermore, the molecular homology analysis, SAR and the molecular binding properties of compound with the active site of a-amylase and a-glucosidase were confirmed through computational analysis. This study has identified the inhibitory potential of a new class of synthesized isoxazoline-thiazolidine-2,4-dione derivatives in controlling both hyperglycemia and type 2 diabetes mellitus without any hepatic toxicity.
Synthesis, biological evaluation, acute toxicity and molecular docking studies of thiazolidine-2,4-diones derivatives as new class of α-glucosidase and α-amylase inhibitors.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.